Pharmacochemistry of the furoxan ring: recent developments

Farmaco. 1993 Feb;48(2):321-34.

Abstract

In the present work recent results obtained in the pharmacochemistry of the furoxan system are reported. In particular, after a brief description of the salient points of the furoxan chemistry, the synthesis and the properties of a series of Nifedipine and Prazosin analogues, containing this heterocyclic system, are described. Since we observed that a few furoxan derivatives are able to elicit both a dose-dependent rise in platelet cGMP levels and to promote a dose-dependent inhibition of AA-induced [Ca++] rise, and that many substituted furoxans show potent vasodilating and antiaggregatory activity, the possibility of using the furoxan system as a lead in the design of new vasodilators is also discussed.

MeSH terms

  • Animals
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • Calcium Channel Blockers / pharmacology
  • Cyclic GMP / blood
  • Guinea Pigs
  • Heart Rate / drug effects
  • Humans
  • In Vitro Techniques
  • Myocardial Contraction / drug effects
  • Nifedipine / analogs & derivatives*
  • Nifedipine / chemical synthesis
  • Nifedipine / pharmacology
  • Oxadiazoles / chemistry
  • Oxadiazoles / pharmacology*
  • Platelet Aggregation Inhibitors / chemical synthesis
  • Platelet Aggregation Inhibitors / pharmacology
  • Prazosin / analogs & derivatives*
  • Prazosin / chemical synthesis
  • Prazosin / pharmacology
  • Vasodilator Agents / chemical synthesis
  • Vasodilator Agents / pharmacology

Substances

  • Calcium Channel Blockers
  • Oxadiazoles
  • Platelet Aggregation Inhibitors
  • Vasodilator Agents
  • furoxans
  • Cyclic GMP
  • Nifedipine
  • Prazosin